Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lorenzo F. Fanchi
Observed names:
L. Fanchi,
L.F. Fanchi,
Lorenzo Fanchi
Institutions:
The Netherlands Cancer Institute,
Oncode Institute
Observed institutions:
University Medical Center Groningen,
The University of Texas MD Anderson Cancer Center,
Utrecht University,
Herlev Hospital,
Wellcome Sanger Institute,
The Netherlands Cancer Institute,
ENPICOM (Netherlands),
Oncode Institute
show all 8
ORCID:
0000-0002-5763-6726
Observed ORCID:
0000-0002-5763-6726
OpenAlex ID:
A5077065834
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
2020
·
Myriam Chalabi
, Lorenzo F. Fanchi
, et al.
·
Nature Medicine
·
1,555
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
2018
·
Krijn K. Dijkstra
, Chiara M. Cattaneo
, et al.
·
Cell
·
1,228
PDF
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
2018
·
Christian U. Blank
, Elisa A. Rozeman
, et al.
·
Nature Medicine
·
930
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
2018
·
Wouter Scheper
, Sander Kelderman
, et al.
·
Nature Medicine
·
607
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
2020
·
Daniel K. Wells
, Marit M. van Buuren
, et al.
·
Cell
·
579
PDF
Tumor organoid–T-cell coculture systems
2019
·
Chiara M. Cattaneo
, Krijn K. Dijkstra
, et al.
·
Nature Protocols
·
438
Antigen receptor repertoire profiling from RNA-seq data
2017
·
Dmitriy A Bolotin
, Stanislav Poslavsky
, et al.
·
Nature Biotechnology
·
345
Reverse TCR repertoire evolution toward dominant low-affinity clones during chronic CMV infection
2020
·
Kilian Schober
, Florian Voit
, et al.
·
Nature Immunology
·
119
Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
2018
·
Jing Liu
, Elisa A. Rozeman
, et al.
·
OncoImmunology
·
74
PDF
Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer
2018
·
M. Chalabi
, L.F. Fanchi
, et al.
·
Annals of Oncology
·
70
T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors
2019
·
Donjete Simnica
, Nuray Akyüz
, et al.
·
OncoImmunology
·
68
PDF
Next‐Generation Immunosequencing Reveals Pathological T‐Cell Architecture in Autoimmune Hepatitis
2020
·
Christoph Schultheiß
, Donjete Simnica
, et al.
·
Hepatology
·
48
PDF
Antigen‐specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy
2016
·
Sander Kelderman
, Bianca Heemskerk
, et al.
·
European Journal of Immunology
·
45
PDF
Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.
2017
·
Elisa A. Rozeman
, Christian U. Blank
, et al.
·
Journal of Clinical Oncology
·
30
High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias
2019
·
Donjete Simnica
, Simon Schliffke
, et al.
·
Frontiers in Immunology
·
29
PDF
Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells
2020
·
Gennaro Prota
, Uzi Gileadi
, et al.
·
Cancer Immunology Research
·
20
(Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses
2017
·
E.A. Rozeman
, L. Fanchi
, et al.
·
Annals of Oncology
·
18
PDF
Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer
2020
·
Donjete Simnica
, Minke Smits
, et al.
·
JCO Precision Oncology
·
10
30 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial)
2018
·
E.A. Rozeman
, K. Sikorska
, et al.
·
Annals of Oncology
·
8
The CMV-Specific CD8+ T Cell Response Is Dominated by Supra-Public Clonotypes with High Generation Probabilities
2020
·
Kilian Schober
, Pim Fuchs
, et al.
·
Pathogens
·
6
PDF
Properties of CD8 T-cell-recognized neoantigens in different tumor types
2025
·
S.L.C. Ketelaars
, M.M. van Buuren
, et al.
·
Immuno-Oncology Technology
·
4
Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
2013
·
Sander Kelderman
, Bianca Heemskerk
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
Abstract B022: Properties of T-cell-recognized neoantigens
2019
·
Pia Kvistborg
, Marit M. van Buuren
, et al.
·
Cancer Immunology Research
·
1
WITHDRAWN: Properties of CD8 T cell recognized neoantigens in different tumor types
2025
·
Steven L.C. Ketelaars
, Marit M. van Buuren
, et al.
·
Immuno-Oncology Technology
Lack of detectable neoantigen depletion in treatment-naïve cancers
2023
·
Maarten Slagter
, Lorenzo F. Fanchi
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Show more works
View as search
Works count:
32
Citation count:
6,234
H-index:
17
I10-index:
18
Year
Topic
Type